Vaxart Plunges 11.55% Despite Strong Norovirus Vaccine Data

On June 13, 2025, Vaxart's stock experienced a significant drop of 11.55% in pre-market trading, marking a notable decline in its share price.

Vaxart recently announced encouraging topline results from its Phase 1 clinical trial for a second-generation oral pill norovirus vaccine. The trial demonstrated significant boosts in important antibody responses, including a 141% increase in GI.1 norovirus antibodies and a 94% rise in GII.4 antibodies. These results indicate that the vaccine is producing much stronger immune responses than previous versions, which could be a game-changer in the fight against norovirus.

Vaxart has also completed the enrollment of its Phase 1 clinical trial evaluating its second-generation oral norovirus vaccine. This development is part of the company's broader program, which includes oral pill vaccines designed to protect against COVID-19, norovirus, and influenza, as well as a therapeutic vaccine.